DURECT Corporation

    Jurisdiction
    United States
    LEI
    549300EW9IYW3V3QPJ86
    ISIN
    US2666055007 (DRRX)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - Specialty & Generic

    Scores

    InsiderPie Expert Score
    51 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    1 / 7

    Profile

    DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. Read full profile

    Fundamentals

    Net revenue
    -€1.02M
    Gross margin
    53.3%
    EBIT
    -€14.27M
    EBIT margin
    1,395.6%
    Net income
    -€2.97M
    Net margin
    290.1%

    Statement period: - (published )

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 172K $138.32K +3.7K Buy

    Earnings Calls

    Latest earnings call: May 13, 2024 (Q1 2024)

    Add to watchlist

    Notifications